Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population

Heart Rhythm

Volumn 13, Issue 5, 2016, Pages 1088-1095

  Sokal, Adam ^a   Lenarczyk, Radoslaw ^a   Kowalski, Oskar ^a   Mitrega, Katarzyna ^a   Pluta, Slawomir ^a   Stabryla Deska, Joanna ^a   Streb, Witold ^a   Urbanik, Zofia ^a   Krzeminski, Tadeusz F ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Biomarkers; Cardiac resynchronization; Collagen turnover; Heart failure; Heart remodeling

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGEN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; METALLOPROTEINASE 2; METALLOPROTEINASE 9; PROCOLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK; SURVIVAL ANALYSIS; BLOOD; HEART FAILURE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CARDIAC RESYNCHRONIZATION THERAPY; COLLAGEN; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; SURVIVAL ANALYSIS;

EID: 84959872463     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.12.036     Document Type: Article

References (37)

1. M. Brignole, A. Auricchio, G. Baron-Esquivias, and et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) Eur Heart J 34 2013 2281 2329
2. A.E. Epstein, J.P. DiMarco, K.A. Ellenbogen, and et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 61 2013 e6 e75
3. Q. Zhang, Y. Zhou, and C.M. Yu Incidence, definition, diagnosis, and management of the cardiac resynchronization therapy nonresponder Curr Opin Cardiol 30 2015 40 49
4. E.S. Chung, A.R. Leon, L. Tavazzi, and et al. Results of the Predictors of Response to CRT (PROSPECT) trial Circulation 117 2008 2608 2616
5. F. Ruschitzka, W.T. Abraham, J.P. Singh, et al. EchoCRT Study Group Cardiac-resynchronization therapy in heart failure with a narrow QRS complex N Engl J Med 369 2013 1395 1405
6. M. Sohal, S.G. Duckett, X. Zhuang, and et al. A prospective evaluation of cardiovascular magnetic resonance measures of dyssynchrony in the prediction of response to cardiac resynchronization therapy J Cardiovasc Magn Reson 16 2014 58
7. S. Lehner, C. Uebleis, F. Schüßler, A. Haug, S. Kääb, P. Bartenstein, S.D. Van Kriekinge, G. Germano, H. Estner, and M. Hacker The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET Eur J Nucl Med Mol Imaging 40 2013 1876 1883
8. M. Gasparini, C. Muto, S. Iacopino, and et al. Low-dose dobutamine test associated with interventricular dyssynchrony: a useful tool to identify cardiac resynchronization therapy responders: data from the LOw dose DObutamine stress-echo test in Cardiac Resynchronization Therapy (LODO-CRT) phase 2 study Am Heart J 163 2012 422 429
9. F. Zannad, and B. Pitt Biomarkers of extracellular matrix turnover Heart Fail Clin 5 2009 589 599
10. A. Yndestad, J.K. Damås, E. Oie, T. Ueland, L. Gullestad, and P. Aukrust Systemic inflammation in heart failure - the whys and wherefores Heart Fail Rev 11 2006 83 92
11. J.P. Araújo, P. Lourenço, A. Azevedo, F. Friões, F. Rocha-Gonçalves, A. Ferreira, and P. Bettencourt Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review J Card Fail 15 2009 256 266
12. S. de Jong, T.A. van Veen, J.M. de Bakker, M.A. Vos, and H.V. van Rijen Biomarkers of myocardial fibrosis J Cardiovasc Pharmacol 57 2011 522 535
13. P.J. Lijnen, T. Maharani, N. Finahari, and J.S. Prihadi Serum collagen markers and heart failure Cardiovasc Hematol Disord Drug Targets 12 2012 51 55
14. H. Krum, M. Elsik, H.G. Schneider, A. Ptaszynska, M. Black, P.E. Carson, M. Komajda, B.M. Massie, R.S. McKelvie, J.J. McMurray, M.R. Zile, and I.S. Anand Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy Circ Heart Fail 4 2011 561 568
15. E. Barasch, J.S. Gottdiener, G. Aurigemma, D.W. Kitzman, J. Han, W.J. Kop, and R.P. Tracy The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study Circ Heart Fail 4 2011 733 739
16. S.H. Poulsen, N.B. Høst, S.E. Jensen, and K. Egstrup Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction Circulation 101 2000 1527 1532
17. R. Eschalier, M. Fertin, R. Fay, C. Bauters, F. Zannad, F. Pinet, and P. Rossignol Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study Circ Heart Fail 6 2013 1199 1205
18. S. Umar, J.J. Bax, M. Klok, R.J. van Bommel, M.H. Hessel, B. den Adel, G.B. Bleeker, M.M. Henneman, D.E. Atsma, E.E. van der Wall, M.J. Schalij, and A. van der Laarse Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy Eur J Heart Fail 10 2008 878 883
19. Y.X. Dong, J.C. Burnett Jr, H.H. Chen, S. Sandberg, Y.Z. Yang, Y. Zhang, P.S. Chen, and Y.M. Cha Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure J Interv Card Electrophysiol 30 2011 241 249
20. N. Lopez-Andrès, P. Rossignol, W. Iraqi, R. Fay, J. Nuée, S. Ghio, J.G. Cleland, F. Zannad, and P. Lacolley Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial Eur J Heart Fail 14 2012 74 81
21. F.G. Spinale Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 2007 1285 1342
22. G.V. Halade, Y.F. Jin, and M.L. Lindsey Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation Pharmacol Ther 139 2013 32 40
23. F. Kramer, and H. Milting Novel biomarkers in human terminal heart failure and under mechanical circulatory support Biomarkers 16 2011 S31 S41
24. R. Lenarczyk, O. Kowalski, B. Średniawa, and et al. Triple-Site Versus Standard Cardiac Resynchronization Therapy Study (TRUST CRT): clinical rationale, design and implementation J Cardiovasc Electrophysiol 20 2009 658 662
25. R. Lenarczyk, O. Kowalski, B. Sredniawa, P. Pruszkowska-Skrzep, M. Mazurek, E. Jȩdrzejczyk-Patej, A. Woźniak, S. Pluta, J. Głowacki, and Z. Kalarus Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing Triple-Site Cardiac Resynchronization Therapy: a substudy of TRUST CRT randomized trial J Cardiovasc Electrophysiol 23 2012 1228 1236
26. J. Schaper, S. Kostin, S. Hein, A. Elsässer, E. Arnon, and R. Zimmermann Structural remodelling in heart failure Exp Clin Cardiol 7 2002 64 68
27. P. Kong, P. Christia, and N.G. Frangogiannis The pathogenesis of cardiac fibrosis Cell Mol Life Sci 71 2014 549 574
28. S. Hein, E. Arnon, S. Kostin, M. Schönburg, A. Elsässer, V. Polyakova, E.P. Bauer, W.P. Klövekorn, and J. Schaper Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms Circulation 107 2003 984 991
29. L. van Heerebeek, C.P. Franssen, N. Hamdani, F.W. Verheugt, G.A. Somsen, and W.J. Paulus Molecular and cellular basis for diastolic dysfunction Curr Heart Fail Rep 9 2012 293 302
30. T.F. Ismail, S.K. Prasad, and D.J. Pennell Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy Heart 98 2012 438 442
31. B. López, A. González, S. Ravassa, J. Beaumont, M.U. Moreno, G. San José, R. Querejeta, and J. Díez Circulating biomarkers of myocardial fibrosis: the need for a reappraisal J Am Coll Cardiol 65 2015 2449 2456
32. H. Izawa, T. Murohara, K. Nagata, and et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2005 2940 2945
33. G. Klappacher, P. Franzen, D. Haab, M. Mehrabi, M. Binder, K. Plesch, R. Pacher, M. Grimm, I. Pribill, H.G. Eichler, and D. Glogar Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis Am J Cardiol 75 1995 913 918
34. B. López, A. González, R. Querejeta, E. Zubillaga, M. Larman, and J. Díez Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin Eur J Heart Fail 17 2015 385 392
35. D.M. Kaye, O. Khammy, J. Mariani, and M.T. Maeder Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure Eur J Heart Fail 15 2013 292 298
36. M.H. Hessel, G.B. Bleeker, J.J. Bax, M.M. Henneman, B. den Adel, M. Klok, M.J. Schalij, D.E. Atsma, and A. van der Laarse Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail 9 2007 1058 1063
37. A. Sokal, M. Zembala, A. Radomski, A. Kocher, J. Pacholewicz, J. Los, E. Jedrzejczyk, M. Zembala, and M. Radomski A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery J Thorac Cardiovasc Surg 137 2009 1218 1224